0.17Open0.17Pre Close0 Volume4.10K Open Interest12.00Strike Price0.00Turnover782.88%IV1265.88%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.17Extrinsic Value100Contract SizeAmericanOptions Type0.3261Delta0.2159Gamma5.24Leverage Ratio-0.0144Theta0.0001Rho1.71Eff Leverage0.0008Vega
Assertio Stock Discussion
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
Friday, 13th December at 8:00 am
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon® (eflapegrastim-x...
Underated/Valued, overlooked, great buy!!!
This one is killin it....
No comment yet